Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.37 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.37 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13485503 | 0.79 | GPR35 (0.36) | — | |
| SCHEMBL15127684 | 0.75 | — | — | |
| SCHEMBL30694157 | 0.72 | TXNRD1 (0.43) | TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL13485481 | 0.72 | TXNRD1 (0.43) | TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL31235202 | 0.70 | PMM2 (0.37) | HTT | |
| SCHEMBL13485506 | 0.69 | MAPT (0.34) | TXNRD1TXNRD3TXNRD2 | |
| SCHEMBL22835493 | 0.68 | SNCA (0.37) | HTT | |
| SCHEMBL13589888 | 0.68 | HTT (0.32) | HTT | |
| SCHEMBL29178876 | 0.67 | CHRNB4 (0.42) | — | |
| SCHEMBL20263723 | 0.66 | NPC1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044084-B1 | MTKI QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-17 | — | — | EP | disclosed |
| US-8492377-B2 | MTKI quinazoline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2013-07-23 | — | — | US | disclosed |
| US-20100029627-A1 | MTKI QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2010-02-04 | — | — | US | disclosed |
| WO-2008006884-A2 | MTKI QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029627-A1 | MTKI QUINAZOLINE DERIVATIVES | NR4A3, NR4A1, NR5A2 | TXNRD1 805/4885TXNRD3 164/4885TXNRD2 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.